Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annu...(ec.gov target _new www.sec.gov M...),Health

Date:5/7/2009

ec.gov" target="_new">www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson Pharmaceutical Research & Development, L.L.C. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.]

    Media inquiries:                Greg Panico       +1 908-240-2011
                                                      +1 908-927-3715

    Investor Relations inquiries:   Louise Mehrotra   +1 732-524-6491
                                    Lesley Fishman    +1 732-524-3922

'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
2. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
5. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
6. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
7. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
8. Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
9. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
10. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
11. Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease